References
Akakura N，et al.Constitutive expression of hypoxiainducible factor-lalpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation.Cancer Res.2001；61：6548-54.
Asaumi H，Watanabe S，Taguchi M，Tashiro M，Otsuki M.Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species.Am J Physiol Gastrointest Liver Physiol.2007；293:G972-8.
Balkwill F，Mantovani A.Inflammation and cancer:back to Virchow？Lancet.2001；357：539-45.
Ballehaninna UK，Chamberlain RS.Serum CA 19-9 as a biomarker for pancreatic cancer—a comprehensive review.Indian J Surg Oncol.2011；2：88-100.
Bansal P，Sonnenberg A.Pancreatitis is a risk factor for pancreatic cancer.Gastroenterology.1995；109：247-51.
Bardeesy N，DePinho RA.Pancreatic cancer biology and genetics.Nat Rev Cancer.2002；2：897-909.
Beatty GL，et al.CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.Science.2011；331：1612-6.
Berezikov E.Evolution of microRNA diversity and regulation in animals.Nat Rev Genet.2011；12：846-60.
Bielas JH，Loeb KR，Rubin BP，True LD，Loeb LA.Human cancers express a mutator phenotype.Proc Natl Acad Sci U S A.2006；103：18238-42.
Brugge WR，Lauwers GY，Sahani D，Fernandez-del Castillo C，Warshaw AL.Cystic neoplasms of the pancreas.N Engl J Med.2004；351：1218-26.
Campbell AS，Albo D，Kimsey TF，White SL，Wang TN.Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion.J Surg Res.2005；123：96-101.
Campisi J，d'Adda di Fagagna F.Cellular senescence:when bad things happen to good cells.Nat Rev Mol Cell Biol.2007；8：729-40.
Carriere C，Young AL，Gunn JR，Longnecker DS，Korc M.Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras.Biochem Biophys Res Commun.2009；382：561-5.
Cavestro GM，Comparato G，Nouvenne A，Sianesi M，Di Mario F.The race from chronic pancreatitis to pancreatic cancer.JOP.2003；4：165-8.
Chan A，et al.Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.Clin Cancer Res.2014；20：5787-95.
Colotta F，Allavena P，Sica A，Garlanda C，Mantovani A.Cancer-related inflammation，the seventh hallmark of cancer:links to genetic instability.Carcinogenesis.2009；30：1073-81.
Cooks T，Harris CC，Oren M.Caught in the cross fire:p53 in inflammation.Carcinogenesis.2014；35：1680-90.
Costello E，Greenhalf W，Neoptolemos JP.New biomarkers and targets in pancreatic cancer and their application to treatment.Nat Rev Gastroenterol Hepatol.2012；9：435-44.
Cote GA，Smith J，Sherman S，Kelly K.Technologies for imaging the normal and diseased pancreas.Gastroenterology.2013；144：1262-71.el.
Crnogorac-Jurcevic T，et al.Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma.Gastroenterology.2005；129：1454-63.
Cuzzocrea S，et al.Rosiglitazone，a ligand of the peroxisome proliferator-activated receptor-gamma，reduces acute pancreatitis induced by cerulein.Intensive Care Med.2004；30：951-6.
Diao L，Chen YG.PTEN，a general negative regulator of cyclin D expression.Cell Res.2007；17：291-2.
DiDonato JA，Hayakawa M，Rothwarf DM，Zandi E，Karin M.A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB.Nature.1997；388：548-54.
Elinav E，et al.Inflammation-induced cancer:crosstalk between tumours，immune cells and microorganisms.Nat Rev Cancer.2013；13：759-71.
Elnemr A，et al.PPARgamma ligand（thiazolidinedione）induces growth arrest and differentiation markers of human pancreatic cancer cells.Int J Oncol.2000；17：1157-64.
Farrow B，Evers BM.Inflammation and the development of pancreatic cancer.Surg Oncol.2002；10：153-69.
Fleisher AS，et al.Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene，hMLHl.Cancer Res.2000；60：4864-8.
Friess H，Guo XZ，Nan BC，Kleeff J，Buchler MW.Growth factors and cytokines in pancreatic carcinogenesis.Ann N Y Acad Sci.1999；880：110-21.
Gansauge S，et al.Genetic alterations in chronic pancreatitis:evidence for early occurrence of p53 but not K-ras mutations.Br J Surg.1998；85：337-40.
Gidekel Friedlander SY，et al.Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras.Cancer Cell.2009；16：379-89.
Glass CK，Saijo K.Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells.Nat Rev Immunol.2010；10：365-76.
Goggins M.Molecular markers of early pancreatic cancer.J Clin Oncol.2005；23：4524-31.
Guerra C，et al.Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice.Cancer Cell.2007；11：291-302.
Hanahan D，Weinberg RA.Hallmarks of cancer:the next generation.Cell.2011；144：646-74.
Hashimoto K，Ethridge RT，Saito H，Rajaraman S，Evers BM.The PPARgamma ligand，15d-PGJ2，attenuates the severity of cerulein-induced acute pancreatitis.Pancreas.2003；27：58-66.
Hengstler JG，et al.Mutation analysis of the cationic trypsinogen gene in patients with pancreatic cancer.Anticancer Res.2000；20：2967-74.
Hidalgo M.Pancreatic cancer.N Engl J Med.2010；362：1605-17.
Hingorani SR，et al.Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.Cancer Cell.2003；4：437-50.
Huang H，et al.Activation of nuclear factor-kappaB in acinar cells increases the severity of pancreatitis in mice.Gastroenterology.2013；144：202-10.
Itzkowitz SH，Yio X.Inflammation and cancerⅣ.Colorectal cancer in inflammatory bowel disease:the role of inflammation.Am J Physiol Gastrointest Liver Physiol.2004；287：G7-17.
Jackson L，Evers BM.Chronic inflammation and pathogenesis of GI and pancreatic cancers.Cancer Treat Res.2006；130：39-65.
Jackson AL，Loeb LA.The contribution of endogenous sources of DNA damage to the multiple mutations in cancer.Mutat Res.2001；477：7-21.
Jacobs EJ，et al.Aspirin use and pancreatic cancer mortality in a large United States cohort.J Natl Cancer Inst.2004；96：524-8.
Jaiswal M，LaRusso NF，Gores GJ.Nitric oxide in gastrointestinal epithelial cell carcinogenesis:linking inflammation to oncogenesis.Am J Physiol Gastrointest Liver Physiol.2001；281：G626-34.
Jaster R，et al.Peroxisome proliferator-activated receptor gamma overexpression inhibits pro-fibrogenic activities of immortalised rat pancreatic stellate cells.J Cell Mol Med.2005；9：670-82.
Jones S，et al.Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.Science.2008；321：1801-6.
Kalthoff H，Roeder C，Brockhaus M，Thiele HG，Schmiegel W.Tumor necrosis factor（TNF）upregulates the expression of p75 but not p55 TNF receptors，and both receptors mediate，independently of each other，up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA.J Biol Chem.1993；268：2762-6.(https://www.daowen.com)
Kang H，et al.Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer.Cell Death Differ.2016；23（3）：484-95.
Keiles S，Kammesheidt A.Identification of CFTR，PRSS1，and SPINK1 mutations in 381 patients with pancreatitis.Pancreas.2006；33：221-7.
Klimstra DS，Longnecker DS.K-ras mutations in pancreatic ductal proliferative lesions.Am J Pathol.1994；145：1547-50.
Kong X，et al.Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients:miR-196a could be a potential marker for poor prognosis.Dig Dis Sci.2011；56：602-9.
Kong X，Li L，Li Z，Xie K.Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases:molecular basis for therapeutic implications.Cytokine Growth Factor Rev.2012；23：343-56.
Kozomara A，Griffiths-Jones S.miRBase:annotating high confidence microRNAs using deep sequencing data.Nucleic Acids Res.2014；42：D68-73.
Li L，et al.Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and beta-catenin signaling in pancreatic ductal adenocarcinoma cells.Gastroenterology.2014；147：485-97.e18.
Liao Z，et al.Guidelines:diagnosis and therapy for chronic pancreatitis.J Interv Gastroenterol.2013；3：133-6.
Lowenfels AB，et al.Pancreatitis and the risk of pancreatic cancer.International Pancreatitis Study Group.N Engl J Med.1993；328：1433-7.
Lowenfels AB，et al.Hereditary pancreatitis and the risk of pancreatic cancer.International Hereditary Pancreatitis Study Group.J Natl Cancer Inst.1997；89：442-6.
Lu H，Ouyang W，Huang C.Inflammation，a key event in cancer development.Mol Cancer Res.2006；4：221-33.
Maire F，et al.Differential diagnosis between chronic pancreatitis and pancreatic cancer:value of the detection of KRAS2 mutations in circulating DNA.Br J Cancer.2002；87：551-4.
Maitra A，Hruban RH.Pancreatic cancer.Annu Rev Pathol.2008；3：157-88.
Maitra A，Fukushima N，Takaori K，Hruban RH.Precursors to invasive pancreatic cancer.Adv Anat Pathol.2005；12：81-91.
Malats N，et al.Cystic fibrosis transmembrane regulator（CFTR）DeltaF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer.PANKRAS II Study Group.Gut.2001；48：70-4.
Malka D，et al.Risk of pancreatic adenocarcinoma in chronic pancreatitis.Gut.2002；51：849-52.
Mazur PK，Hemer A，Neff F，Siveke JT.Current methods in mouse models of pancreatic cancer.Methods Mol Biol.2015；1267：185-215.
Mazzieri R，et al.Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.Cancer Cell.2011；19：512-26.
McDade TP，Perugini RA，Vittimberga FJ Jr，Carrigan RC，Callery MP.Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells.J Surg Res.1999；83：56-61.
McKay CJ，Glen P，McMillan DC.Chronic inflammation and pancreatic cancer.Best Pract Res Clin Gastroenterol.2008；22：65-73.
Mitchem JB，et al.Targeting tumor-infiltrating macrophages decreases tumor-initiating cells，relieves immunosuppression，and improves chemotherapeutic responses.Cancer Res.2013；73：1128-41.
Morcos NY，Zakhary NI，Said MM，Tadros MM.Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients.Ecancermedicalscience.2013；7：305.
Morris JP，Cano DA，Sekine S，Wang SC，Hebrok M.Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice.J Clin Invest.2010；120：508-20.
Mueller E，et al.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U S A.2000；97：10990-5.
Neesse A，et al.Stromal biology and therapy in pancreatic cancer.Gut.2011；60：861-8.
Olive KP，et al.Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.Science.2009；324：1457-61.
Pan X，et al.Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.Clin Cancer Res.2008；14：8143-51.
Rachagani S，et al.Clinical implications of miRNAs in the pathogenesis，diagnosis and therapy of pancreatic cancer.Adv Drug Deliv Rev.2015；81：16-33.
Raimondi S，Maisonneuve P，Lowenfels AB.Epidemiology of pancreatic cancer:an overview.Nat Rev Gastroenterol Hepatol.2009；6：699-708.
Reding T，et al.A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model（WBN/Kob rats）：significant reduction of macrophage infiltration and fibrosis.Gut.2006；55：1165-73.
Rozenblum E，et al.Tumor-suppressive pathways in pancreatic carcinoma.Cancer Res.1997；57：1731-4.
Sakorafas GH，Tsiotou AG.Pancreatic cancer in patients with chronic pancreatitis:a challenge from a surgical perspective.Cancer Treat Rev.1999；25：207-17.
Schernhammer ES，et al.A prospective study of aspirin use and the risk of pancreatic cancer in women.J Natl Cancer Inst.2004；96：22-8.
Schneider A，Whitcomb DC.Hereditary pancreatitis:a model for inflammatory diseases of the pancreas.Best Pract Res Clin Gastroenterol.2002；16：347-63.
Schultz NA，et al.MicroRNA biomarkers in whole blood for detection of pancreatic cancer.JAMA.2014；311：392-404.
Shi C，Merchant N，Newsome G，Goldenberg DM，Gold DV.Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.Arch Pathol Lab Med.2014；138：220-8.
Shimizu K，et al.Thiazolidinedione derivatives as novel therapeutic agents to prevent the development of chronic pancreatitis.Pancreas.2002；24：184-90.
Suzuki J，et al.Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases.Expert Opin Investig Drugs.2011；20：395-405.
Uomo I，Miraglia S，Pastorello M.Inflammation and pancreatic ductal adenocarcinoma:a potential scenario for novel drug targets.JOP.2010；11：199-202.
Vincent A，Herman J，Schulick R，Hruban RH，Goggins M.Pancreatic cancer.Lancet.2011；378：607-20.
Vogelstein B，et al.Genetic alterations during colorectaltumor development.N Engl J Med.1988；319：525-32.
Wang LW，et al.Prevalence and clinical features of chronic pancreatitis in China:a retrospective multicenter analysis over 10 years.Pancreas.2009；38：248-54.
Wiseman H，Halliwell B.Damage to DNA by reactive oxygen and nitrogen species:role in inflammatory disease and progression to cancer.Biochem J.1996；313（Pt 1）：17-29.
Xie D，Xie K.Pancreatic cancer stromal biology and therapy.Genes Dis.2015；2：133-43.
Yu JH，Kim H.Oxidative stress and cytokines in the pathogenesis of pancreatic cancer.J Cancer Prev.2014；19：97-102.
Zagury D，Burny A，Gallo RC.Toward a new generation of vaccines:the anti-cytokine therapeutic vaccines.Proc Natl Acad Sci U S A.2001；98：8024-9.